Polyrizon Reports Positive Preclinical Data on Nasal Protection Platform

Polyrizon Ltd. ( (PLRZ) ) has provided an announcement.

On May 21, 2025, Polyrizon Ltd. announced positive preclinical results for its nasal protection platform. The studies demonstrated strong mucoadhesion and broad surface coverage in ex vivo nasal tissue models, suggesting the potential for effective localized protection and drug delivery. The research, conducted with Prof. Fabio Sonvico’s laboratory, highlighted the formulation’s ability to rapidly and uniformly coat nasal mucosa, maintaining strong attachment even under physiological conditions. This development could enhance Polyrizon’s positioning in the biotech industry by showcasing the efficacy of its innovative intranasal delivery systems.

More about Polyrizon Ltd.

Polyrizon Ltd. is a development stage biotech company that specializes in creating innovative intranasal hydrogels. These hydrogels are delivered as nasal sprays to form a protective barrier in the nasal cavity, potentially shielding against viruses and allergens. The company’s proprietary Capture and Contain (C&C) hydrogel technology acts as a ‘biological mask,’ and they are also developing the Trap and Target (T&T) technology for nasal delivery of active pharmaceutical ingredients.

Average Trading Volume: 20,756,645

Technical Sentiment Signal: Strong Sell

Current Market Cap: $2.31M

See more insights into PLRZ stock on TipRanks’ Stock Analysis page.